Ajanta Pharma Full Year 2025 Earnings: Revenues Beat Expectations, EPS In Line

Ajanta Pharma (NSE:AJANTPHARM) Full Year 2025 Results

Key Financial Results

• Revenue: ₹47.4b (up 13% from FY 2024).
• Net income: ₹9.20b (up 13% from FY 2024).
• Profit margin: 19% (in line with FY 2024).
• EPS: ₹73.56 (up from ₹64.82 in FY 2024).

Our free stock report includes 1 warning sign investors should be aware of before investing in Ajanta Pharma. Read for free now.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ajanta Pharma Revenues Beat Expectations

Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.

Performance of the Indian Pharmaceuticals industry.

The company's shares are down 3.0% from a week ago.

Risk Analysis

We should say that we've discovered 1 warning sign for Ajanta Pharma that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.